Symptom-based tendencies of *Helicobacter pylori* eradication in patients with functional dyspepsia

Ling Lan, Jing Yu, Yu-Long Chen, Ya-Li Zhong, Hao Zhang, Chang-He Jia, Yuan Yuan, Bo-Wei Liu

**Abstract**

**AIM:** To investigate whether there were symptom-based tendencies in the *Helicobacter pylori* (*H. pylori*) eradication in functional dyspepsia (FD) patients.

**METHODS:** A randomized, single-blind, placebo-controlled study of *H. pylori* eradication for FD was conducted. A total of 195 FD patients with *H. pylori* infection were divided into two groups: 98 patients in the treatment group were treated with rabeprazole 10 mg twice daily for 2 wk, amoxicillin 1.0 g and clarithromycin 0.5 g twice daily for 1 wk; 97 patients in the placebo group were given placebos as control. Symptoms of FD, such as postprandial fullness, early satiety, nausea, belching, epigastric pain and epigastric burning, were assessed 3 mo after *H. pylori* eradication.

**RESULTS:** By per-protocol analysis in patients with successful *H. pylori* eradication, higher effective rates of 77.2% and 82% were achieved in the patients with epigastric pain and epigastric burning than in the placebo group (*P* < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 46%, 36%, 52.5% and 33.3%, respectively, and there was no significant difference from the placebo group (39.3%, 27.1%, 39.1% and 31.4%) (*P* > 0.05). In 84 patients who received *H. pylori* eradication therapy, the effective rates for epigastric pain (73.8%) and epigastric burning (80.7%) were higher than those in the placebo group (*P* < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 41.4%, 33.3%, 50% and 31.4%, respectively, and did not differ from those in the placebo group (*P* > 0.05). By intention-to-treat analysis, patients with epigastric pain and epigastric burning in the treatment group achieved higher effective rates of 60.8% and 65.7% than the placebo group (33.3% and 31.8%) (*P* < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 34.8%, 27.9%, 41.1% and 26.7% respectively in the treatment group, with no significant difference from those in the placebo group (34.8%, 23.9%, 35.3% and 27.1%) (*P* > 0.05).

**CONCLUSION:** The efficacy of *H. pylori* eradication has symptom-based tendencies in FD patients. It may be effective in the subgroup of FD patients with epigastric pain syndrome.

© 2011 Baishideng. All rights reserved.

**Key words:** *Helicobacter pylori*; Functional dyspepsia; Eradication; Symptom

**Peer reviewer:** Justin C Wu, Professor, Department of Medicine and Therapeutics, The Chinese University of Hong Kong,
INTRODUCTION

Functional dyspepsia (FD) is considered to possess a wide spectrum of nonspecific upper gastrointestinal symptoms without any organic alteration, accounting for 60% of patient referrals to gastroenterology clinics. Despite being barely life-threatening, this disease can lead to a poor quality of life and a high economic burden in the patients.

However, without a clear understanding of its pathogenesis, the optional clinical strategy for FD remains a controversial issue. *Helicobacter pylori* (*H. pylori*) is considered to play a role in the pathogenesis of FD, and therefore, *H. pylori* detection and eradication are performed for FD treatment. But it is still dubious that patients with FD can benefit from *H. pylori* eradication. In our opinion, one of the factors that could contribute to the various outcomes of trials regarding the efficacy of *H. pylori* eradication for FD may be the diversity and inconsistency in FD symptoms, suggesting that this strategy might be effective only for certain dyspeptic symptoms in FD patients.

We conducted a prospective randomized, single-blind and placebo-controlled study and analyzed the efficacy of *H. pylori* eradication therapy for FD patients with *H. pylori* infection to find symptom-based predictors that can guide the clinical application of *H. pylori* detection and eradication.

MATERIALS AND METHODS

Patients

Patients with FD were admitted to the digestive outpatient clinics of three medical centers.

Patients who met the following criteria were enrolled into this study: (1) aged 18-75 years; (2) a definitive diagnosis of FD defined by Rome III criteria (2006); (3) absence of organic diseases, such as ulcer, bleeding, erosion, atrophy, tumor, and esophagitis in gastroscopic examination; (4) laboratory tests, ultrasonography, and X-ray showing no structural diseases in other organs, such as liver, gall bladder, pancreas, kidney, intestine, and colon; (5) both rapid urease test (RUT) and 13C-urea breath test (13C-UBT) confirmed *H. pylori* infection; and (6) not receiving antacids, antibiotics, prokinetic drugs, or nonsteroidal anti-inflammatory drugs within the previous 4 wk.

We excluded the patients who (1) had a drug hypersensitivity history; (2) were previously treated with *H. pylori* eradication therapy; (3) were complicated with irritable bowel syndrome (defined by Rome III criteria); (4) were pregnant or nursing; (5) could not describe subjective complaint accurately; (6) were complicated with diabetes, connective tissue disease, neuromuscular disease, or any other severe systematic diseases; (7) had a history of abdominal surgeries; and (8) drank alcohol more than 40 g a day.

This study was approved by the Institutional Review Board and the Ethics Committee of each medical center and was conducted in accordance with the Helsinki Declaration. Written informed consent was obtained from each subject before enrollment into this study.

Intervention

Gastroscopy and 13C-UBT were performed, and samples of the gastric mucosa were collected during gastroscopy and used for RUT testing. Patients who were positive in both the RUT and 13C-UBT tests were considered suitable candidates for the proposed *H. pylori* eradication therapy. Patients were blinded to this study and randomly assigned by an independent investigator using a computer-generated random number table into one of the two groups, the treatment group and placebo group. The allocation ratio was 1:1. Patients in the treatment group were administered with rabeprazole 10 mg bd, amoxicillin 1 g bd, and clarithromycin 500 mg bd for 1 wk; patients in the placebo group were given placebos as control. No other medication was used during the proposed treatment.

Data collection and follow-up

The symptoms of suitable candidates were recorded on admission, and the proposed 2-wk eradication therapy was administered. Patients were returned for a 13C-UBT test 4 wk after completing the therapy, wherein negative results were considered as definitive evidence of successful eradication. All patients were followed up for 3 mo.

Assessment of clinical efficacy

Six common symptoms of FD, including postprandial fullness, early satiety, nausea, belching, epigastric pain and epigastric burning, were assessed before and 3 mo after the eradication therapy. Symptom scores were graded according to severity as follows: (0) absent; (1) being aware of symptoms but no interference with daily activities; (2) having persistent discomfort with some interference with daily activities; (3) having severe discomfort and being unable to conduct daily work; and (4) suffering from worsening symptoms and having an extreme influence on daily life.

Clinical efficacy was calculated using the reduction rate of the total score of the six symptoms with the following formula: Reduction rate = (total score before treatment - total score after treatment)/ total score before treatment × 100%.

If the reduction rate was ≥ 75%, the patient was considered to experience clinical recovery; a reduction rate ≥ 50% referred to a significant improvement, a reduction
Lan L et al. *H. pylori* eradication and dyspeptic symptoms

rate ≥ 25% meant an improvement, and a rate < 25% meant invalidation. The total effective rate was calculated based on the clinical recovery rate and the significant improvement rate.

**Safety assessment**

Before treatment and during the follow-up, the basic vital signs and laboratory results, including routine blood, urine and stool tests, were monitored and documented. Any suspected adverse events observed during treatment were also recorded for further analysis.

**Statistical analysis**

Sample size was calculated based on the assumption of a 40% response in the drug arm vs 20% in placebo arm using the z statistic to compare dichotomous variables with α = 0.05 (two-tailed) and β = 0.20. The estimated sample size was 81 patients per arm. All data were processed using SPSS 11.0. The effective rates of symptoms were analyzed according to per-protocol (PP) and intent-to-treat (ITT) methods. The χ² test with 2 × 2 tables was used to analyze the efficacy. *P* < 0.05 was considered significant difference.

**RESULTS**

**Patient population**

From September 2008 to May 2010, 195 FD patients with *H. pylori* infection were enrolled into this study. Number, mean age, gender distribution and total scores of symptoms before treatment were similar in the two groups (Table 1).

**H. pylori eradication rate and safety analysis**

Totally, 195 FD patients with *H. pylori* infection were included. Twenty-two were excluded for discontinuation of medication due to severe diarrhea (3 in the treatment group) or for being lost to follow-up (11 in the treatment group and 8 in the placebo group). The others (84 in the treatment group and 89 in the placebo group) received complete treatment and follow-up examinations on schedule. In the treatment group, the successful *H. pylori* eradication rate was 85.7% (72/84).

Adverse reactions documented during treatment included: mild diarrhea in 7 cases, severe diarrhea in 3 cases, stomach discomfort in 4 cases, and simultaneous diarrhea and stomach discomfort in 1 case. Except for one patient who withdrew due to severe, unbearable diarrhea, the adverse events in the patients disappeared spontaneously after the eradication treatment. The basic vital signs and routine blood, urine and stool tests were normal in all the participants.

**Total clinical efficacy**

By PP analysis, in 72 patients with successful *H. pylori* eradication, the total effective rate was 44.4% 3 mo after treatment. In 84 patients who received *H. pylori* eradication therapy, the total effective rate was 42.9%, which was higher than that in the 89 patients of the placebo group (21.4%) (*P* < 0.05) (Table 2).

By ITT analysis, the total effective rate was 36.7% in the treatment group, and 19.6% in the placebo group. There was significant difference between the two groups (*P* < 0.05) (Table 2).

**Efficacy for symptom improvement**

By PP analysis 3 mo after treatment, among the 72 patients with successful *H. pylori* eradication, those with epigastric pain and epigastric burning achieved higher effective rates of 77.2% and 82% than the patients in the placebo group (38.2% and 38.2%) (*P* < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 46%, 36%, 52.5% and 33.3%, and 39.3%, 27.1%, 39.1% and 31.4%, respectively in the placebo group (*P* > 0.05) (Table 3 and Figure 1).

Correspondingly, in 84 patients who received *H. pylori* eradication therapy, the effective rates for epigastric pain (73.8%) and epigastric burning (80.7%) were higher than in the placebo group (*P* < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 41.4%, 33.3%, 50% and 31.4%, respectively, and did not differ from those in the placebo group (*P* > 0.05) (Table 3 and Figure 1).

Similar results were obtained by ITT analysis. In the treatment group, patients with epigastric pain and epigastric burning also achieved higher effective rates of 60.8% and 68.5% respectively, compared with the placebo group.
and 65.7% than those in the the placebo group (33.3% and 31.8%) (P < 0.05). The effective rates for postprandial fullness, early satiety, nausea and belching were 34.8%, 27.9%, 41.1% and 26.7% in the treatment group, and 34.8%, 23.9%, 35.3% and 27.1% in the placebo group (P > 0.05) (Table 3 and Figure 2).

**DISCUSSION**

FD is a common disease, accounting for a majority of upper gastrointestinal symptoms. The pathogenesis of FD is unknown. Various pathophysiological mechanisms, such as gastroduodenal dyskinesia[8], visceral parasthesia[9], vagal dysfunction[10], *H. pylori* infection[11], and psychosocial factors[8], have been proposed to promote the development of FD. Without a clear understanding of its pathogenesis, it is not surprising that standard and effective strategies for treatment of this disease are still unavailable. Consequently, patients with FD now receive symptomatic treatment with prokinetics, antacids, and digestive enzymes empirically, which are prone to unfavorable responses and an extremely high risk of relapse.

*H. pylori* infection is the sole cause of FD that can be successfully eliminated by well-established medical interventions. Furthermore, 40%-60% of FD patients suffer from a detectable *H. pylori* infection[12], which can induce chronic inflammation and in turn the development of symptoms[13]. Evidence suggests that *H. pylori*-associated dyspepsia is caused by effects of the bacteria, such as increased secretion of gastric acid, elevated fasting and postprandial levels of serum gastrin, and declines in somatostatin in gastric mucosa. All these abnormalities can be corrected after *H. pylori* eradication[11-13]. If symptomatic benefits can be achieved after *H. pylori* eradication, the potential implications for this treatment will be enormous.

Unfortunately, whether *H. pylori* eradication is beneficial in FD remains controversial. Several studies have demonstrated that *H. pylori* eradication is efficacious[13-17]. A double-blind study of Asian populations suggested that patients with FD benefit from the *H. pylori* treat-
ment, who gained as much as a 13-fold greater chance for symptom improvement[19]. Another systematic review of FD patients with Helicobacter pylori infection showed that improvement of symptoms could be achieved by up to 3.5 folds with Helicobacter pylori eradication therapy[19].

Other clinical trials, however, have noted that Helicobacter pylori eradication therapy has a moderate but statistically significant effect on FD patients with Helicobacter pylori infection[20,28]. A long-term study attributed the relief of symptoms to natural fluctuations in dyspeptic symptoms[21]. Evenly, low relief rates[22] and the persistence of symptoms[23] were observed in some reports, indicating no benefit of Helicobacter pylori eradication. Some researchers also found that dyspeptic symptoms had a negative correlation with the severity of Helicobacter pylori-associated inflammation and oxidative damage in FD patients[21].

Nevertheless, in most trials, the follow-up period was less than 1 year, creating a dearth of information about the long-term effects of Helicobacter pylori eradication. Recently, several long-term prospective researches have shown promising benefits[24,25]. Maconi et al.[26] reported that at a 7-year follow-up, 33.9% of patients with successful Helicobacter pylori eradication were more likely to be asymptomatic. This percentage was slightly higher than in symptom-free patients with persisted bacteria infection. Yet, there were some confounding factors in the study. Some patients continued to use antisecretory agents, and 40% of patients still used or had been using anti-dyspeptic medications, which might bias the results and render them disputable[24]. Therefore, the evidence that FD patients with Helicobacter pylori infection benefit from Helicobacter pylori eradication therapy is inconclusive[21].

The consensus on Helicobacter pylori treatment in China, reached in 2003[27], and its new version published in 2007[28], recommended but did not stipulate Helicobacter pylori eradication therapy in “some patients with FD” or those who had “dyspeptic symptoms that were accompanied by chronic gastritis.” As such, questions on whether routine Helicobacter pylori detection should be applied in patients with FD, whether Helicobacter pylori eradication treatment must be conducted in these patients, and whether the relief of symptoms can be expected following successful eradication have become critical issues. These issues can result in negative consequences, including over-examination and over-treatment, vague evaluations of prognoses, panic psychology in patients with Helicobacter pylori infection, and decreased treatment compliance among irresponsible patients.

To our knowledge, no study has yet focused on the symptom-based tendencies of Helicobacter pylori eradication. Based on our prospective study, patients with epigastric pain and epigastric burning could experience greater improvement 3 mo after treatment than those with postprandial fullness, early satiety, nausea, and belching. The Rome III consensus classifies FD into two subgroups: postprandial distress syndrome, which presents with postprandial fullness, early satiety, postprandial nausea and over-belching; and epigastric pain syndrome, which features epigastric pain or epigastric burning[11]. This indicated that Helicobacter pylori eradication might be more effective in the subgroup of FD patients with epigastric pain syndrome.

But the mechanism of this symptom selectivity and tendency of Helicobacter pylori eradication therapy, however, is unknown. Gastric emptying in patients with FD is usually delayed or accelerated. The former can lead to abdominal distention, early satiety and nausea, and the latter can result in epigastric pain[13]. Helicobacter pylori infection is associated with faster gastric emptying and aggravates abdominal pain[13]. This result supports our findings that Helicobacter pylori eradication significantly improves the symptoms of epigastric pain. With regard to the relief of epigastric burning in our patients, the intake of antacids might be a half-convincing explanation.

In the further study, we will classify FD patients into two subgroups by the Rome III consensus to observe the symptom response to Helicobacter pylori eradication therapy, in order to investigate whether the efficacy of Helicobacter pylori eradication can be predicted by assessing the initial dyspeptic symptoms.

There are, however, regional differences in the prevalence of various dyspeptic symptoms in patients with FD. For instance, compared with Asian populations, the symptoms of epigastric pain and epigastric burning are more common in Western FD patients[20]; there is a higher prevalence of Helicobacter pylori infection in Asian populations than in Western populations[30]. Hence, global multicenter studies regarding the symptom-based tendencies of Helicobacter pylori eradication treatment are needed for further evaluation of this regimen.

REFERENCES


Talley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756-1780


